21038-63-1

Basic information

• Product Name: 1H-pyrido[2,3-d][1,3]oxazine-2,4-dione
• Synonyms: 1H,2H,4H-pyrido[2,3-d][1,3]oxazine-2,4-dione;3-Azaisatoic anhydride;2H-Pyrido[2,3-d][1,3]oxazine-2,4(1H)-dione;1H-pyrido[2,3-d][1,3]oxazine-2,4-dione
• CAS NO: 21038-63-1
• Molecular Formula: C₇H₄N₂O₃
• Molecular Weight: 164.11826
• Mol File: 21038-63-1.mol
• Article Data: 15

Chemical Properties

• Melting Point: 195.0 °C
• Appearance: /
• Density: 1.498 g/cm3
• Refractive Index: 1.593
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 9.13±0.20(Predicted)
• CAS DataBase Reference: 1H-pyrido[2,3-d][1,3]oxazine-2,4-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-pyrido[2,3-d][1,3]oxazine-2,4-dione(21038-63-1)
• EPA Substance Registry System: 1H-pyrido[2,3-d][1,3]oxazine-2,4-dione(21038-63-1)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 21038-63-1(Hazardous Substances Data)

Usage

Synthesis Reference(s)

Journal of Heterocyclic Chemistry, 22, p. 193, 1985 DOI: 10.1002/jhet.5570220147

InChI:InChI=1/C7H4N2O3/c10-6-4-2-1-3-8-5(4)9-7(11)12-6/h1-3H,(H,8,9,11)

Upstream product

• 5345-47-1 2-aminopyridin-3-carboxylic acid 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 699-98-9 Pyridine-2,3-dicarboxylic anhydride 
• 541-41-3 chloroformic acid ethyl ester 
• 5860-70-8 2-Aminocarbonylnicotinic acid 
• 23411-04-3 2-benzoyloxycarbamoyl-nicotinic acid 

Downstream Products

• 5654-95-5 1H-pyrrolo[2,3-b]pyridine-2,3-dione 
• 565448-79-5 1-(3-methylbutyl)-2H-pyrido[2,3-d][1,3]oxazine-2,4(1H)-dione 
• 1437787-27-3 4-benzyl-2-morpholino-3H-pyrido[2,3-e][1,4]diazepin-5(4H)-one 
• 1437787-26-2 4-benzyl-2-(pyrrolidin-1-yl)-3H-pyrido[2,3-e][1,4]diazepin-5(4H)-one 
• 1437787-11-5 4-Benzyl-2-thioxo-3,4-dihydro-1H-pyrido[2,3-e][1,4]diazepin-5(2H)-one 
• 1437787-08-0 4-benzyl-3,4-dihydro-1H-pyrido[2,3-e][1,4]diazepine-2,5-dione 
• 1003023-69-5 (S)-3-benzyl-3,4-dihydro-1H-pyrido[2,3-e][1,4]diazepine-2,5-dione 
• 1073230-19-9 1-[4-(trifluoromethyl)benzyl]-2H-pyrido[2,3-d][1,3]oxazine-2,4(1H)-dione 
• 58536-96-2 2-allylamino-1-<(4-fluorophenyl)methyl>pyrido<2,3-d>pyrimidine-4(1H)-one 
• 58536-94-0 1-<(4-fluorophenyl)methyl>-2-methylaminopyrido<2,3-d>pyrimidin-4(1H)-one 
• 58536-99-5 2-ethylamino-1-<(4-fluorophenyl)methyl>pyrido<2,3-d>pyrimidine-4(1H)-one 
• 58536-95-1 2-dimethylamino-1-<(4-fluorophenyl)methyl>pyrido<2,3-d>pyrimidin-4(1H)-one 
• 97484-90-7 9-(4-Fluoro-benzyl)-2,3,4,9-tetrahydro-1,4a,8,9-tetraaza-anthracen-10-one 
• 97510-73-1 5-<(4-fluorophenyl)methyl>isoxazolo<4,5-c><1,8>naphthyrimidin-4(5H)-one 

Relevant articles and documents

Structure-activity relationship and molecular modelling studies of quinazolinedione derivatives MMV665916 as potential antimalarial agent

A series of new quinazolinedione derivatives have been readily synthesized and evaluated for their in vitro antiplasmodial growth inhibition activity. Most of the compounds inhibited P. falciparum FcB1 strain in the low to medium micromolar concentration. The 2-ethoxy 8ag’, 2-trifluoromethoxy 8ai’ and 4-fluoro-2-methoxy 8ak’ showed the best inhibitory activity with EC50 values around 5 μM and were non-toxic to the primary human fibroblast cell line AB943. However, these compounds were less potent than the original hit MMV665916, which showed remarkable growth inhibition with EC50 value of 0.4 μM and presented the highest selectivity index (SI > 250). In addition, a novel approach for determining the docking poses of these quinazolinedione derivatives with their potential protein target, the P. falciparum farnesyltransferase PfFT, was investigated.

A convenient synthesis of new pyrido[3,2-e][1,4]diazepine-2,5-diones and pyrido[2,3-e][1,4]diazepine-2,5-diones

A convenient synthesis of a series of pyrido[3,2-e][1,4]-diazepine-2,5- diones 8 and pyrido[2,3-e][1,4]diazepine-2,5-diones 9, is reported using the condensation of α-amino acid methyl ester derivatives with 1H-pyrido[3,2-d][1,3]oxazine-2,4-dione and 1H-p

NOVEL 1,8-NAPHTHYRIDINE COMPOUNDS

The present invention relates to naphthyridine compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.